KPIs & Operating Metrics(New)
Growth Metrics

Astrazeneca (AZN) Short term Debt (2016 - 2025)

Historic Short term Debt for Astrazeneca (AZN) over the last 14 years, with Q4 2025 value amounting to -$3.5 billion.

  • Astrazeneca's Short term Debt fell 24916.56% to -$3.5 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$3.5 billion, marking a year-over-year decrease of 24916.56%. This contributed to the annual value of -$3.5 billion for FY2025, which is 24916.56% down from last year.
  • Per Astrazeneca's latest filing, its Short term Debt stood at -$3.5 billion for Q4 2025, which was down 24916.56% from -$6.6 billion recorded in Q3 2025.
  • Astrazeneca's Short term Debt's 5-year high stood at $5.3 billion during Q4 2022, with a 5-year trough of -$6.6 billion in Q3 2025.
  • Moreover, its 5-year median value for Short term Debt was -$2.3 billion (2022), whereas its average is -$1.5 billion.
  • Over the last 5 years, Astrazeneca's Short term Debt had its largest YoY gain of 22012.05% in 2022, and its largest YoY loss of 170419.58% in 2022.
  • Astrazeneca's Short term Debt (Quarter) stood at $1.7 billion in 2021, then surged by 220.12% to $5.3 billion in 2022, then dropped by 3.48% to $5.1 billion in 2023, then tumbled by 54.44% to $2.3 billion in 2024, then crashed by 249.17% to -$3.5 billion in 2025.
  • Its Short term Debt was -$3.5 billion in Q4 2025, compared to -$6.6 billion in Q3 2025 and -$3.8 billion in Q1 2025.